IFRS results Q1 2018

IFRS results Q1 2018

HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of high-priced special pharmaceuticals from the indication areas oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the company...
Annual Report 2017

Annual Report 2017

HAEMATO AG is a listed pharmaceutical company with a focus on the growth markets of special pharmaceuticals, primarily in the high-priced indication areas of oncology and HIV as well as rheumatism, neurology and cardiovascular diseases. HAEMATO AG had a successful...
2017: Preliminary IFRS results

2017: Preliminary IFRS results

2017: According to the preliminary IFRS results, Haemato AG increased its sales by 5.2% to EUR 289.9 million. In 2017, HAEMATO AG, Berlin (ISIN: DE0006190705), achieved an IFRS group turnover of €289,9m (previous year: €275.6m), an operating result (EBIT) of €9.4...
IFRS Results Q3 2017

IFRS Results Q3 2017

HAEMATO AG is a listed pharmaceutical company with focus on the growth markets of high-end specialty pharmaceuticals in the indication groups of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house...
Interim report second quarter 2017

Interim report second quarter 2017

HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of patent-free and patent-protected drugs primarily in the high-price indicative areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiac, circulatory diseases....
Q1 Results 2017

Q1 Results 2017

IFRS result Q1 2017, sales EUR 67.9 million (previous year: EUR 67.9 million), EBIT EUR 2.8 million (previous year: EUR 3.5 million) HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 67.9 million in the first quarter 2017 at the previous...